Core Insights - Amlitelimab, a monoclonal antibody targeting OX40-ligand, shows positive results in three phase 3 studies for moderate-to-severe atopic dermatitis, demonstrating significant improvements in skin clearance and disease severity compared to placebo [1][2][3] Study Results - The studies COAST 1, COAST 2, and SHORE were presented at the AAD Annual Meeting, indicating that amlitelimab is generally well-tolerated [1][2] - In COAST 1, the primary endpoint was met with 21.1% and 22.5% of patients achieving a validated investigator global assessment scale for AD (vIGA-AD) of 0 or 1 for Q4W and Q12W dosing respectively, compared to 9.2% for placebo [5] - COAST 2 results showed 25.3% and 25.7% of patients achieving vIGA-AD 0/1 for Q4W and Q12W dosing respectively, against 14.8% for placebo [8] - In the SHORE study, 28.7% and 32.3% of patients achieved vIGA-AD 0/1 for Q4W and Q12W dosing respectively, compared to 16.8% for placebo [9] Efficacy and Safety - Amlitelimab demonstrated progressively increasing efficacy over the treatment period with no evidence of plateau at Week 24 [6] - The safety profile was consistent with previous data, with common treatment-emergent adverse events including nasopharyngitis and dermatitis atopic, but overall incidence rates were low [12] - Malignancy rates were low (<1%) across the studies, with no severe injection site reactions reported [12][13] Future Outlook - Sanofi anticipates results from the ESTUARY phase 3 extension study evaluating Q12W maintenance dosing and long-term safety in H2 2026 [14] - Amlitelimab is still in clinical development, and its safety and efficacy have not yet been evaluated by regulatory authorities [14][18]

Core Insights - Amlitelimab, a monoclonal antibody targeting OX40-ligand, shows positive results in three phase 3 studies for moderate-to-severe atopic dermatitis, demonstrating significant improvements in skin clearance and disease severity compared to placebo [1][2][3] Study Results - The studies COAST 1, COAST 2, and SHORE were presented at the AAD Annual Meeting, indicating that amlitelimab is well-tolerated and effective as both monotherapy and in combination with topical therapies [1][4] - In COAST 1, 21.1% of patients on Q4W and 22.5% on Q12W achieved a validated investigator global assessment scale score of 0 or 1, compared to 9.2% in the placebo group [5] - COAST 2 showed 25.3% and 25.7% of patients on Q4W and Q12W respectively achieving the same score, against 14.8% in the placebo group [7] - In the SHORE study, 28.7% on Q4W and 32.3% on Q12W achieved the primary endpoint, compared to 16.8% in the placebo group [7] Efficacy and Safety - Amlitelimab demonstrated progressively increasing efficacy over the treatment period with no evidence of plateau at Week 24 [6] - The safety profile was consistent with previous data, with common treatment-emergent adverse events including nasopharyngitis and dermatitis atopic, but overall incidence rates were low [10] - Malignancy rates were low (<1%) across the studies, with no severe injection site reactions reported [10][11] Future Outlook - Results from the ESTUARY phase 3 extension study, evaluating Q12W maintenance dosing and long-term safety, are expected in H2 2026 [12] - Amlitelimab is still in clinical development and has not yet been evaluated by regulatory authorities [12][16]

Core Viewpoint - Apogee Therapeutics Inc. (NASDAQ:APGE) is identified as one of the 13 stocks with significant upside potential, despite recent adjustments in price targets and sales forecasts by analysts [1][2]. Group 1: Analyst Adjustments - Jefferies has lowered its price target for Apogee Therapeutics from $98 to $95 while maintaining a Buy rating [1]. - The risk-adjusted peak sales forecast for Apogee's '279 combination therapy has been reduced from $1.8 billion to $1.6 billion due to anticipated limitations in high-risk patients [1]. - The share price of Apogee fell by 6% following the discontinuation of Amgen's OX40 collaboration, which has influenced analyst expectations [2]. Group 2: Market Context - The discontinuation of the OX40 collaboration and the deprioritization of amlitelimab by Sanofi are significant events impacting Apogee's market position [2]. - Despite these challenges, analysts do not expect Kaposi's Sarcoma to significantly affect the commercial potential of OX40 therapies, although a potential black box warning for high-risk populations is anticipated [2]. - Apogee Therapeutics focuses on developing treatments for atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications [3].

Core Viewpoint - The decline in Sanofi's stock on February 12, 2026, is primarily attributed to sudden management changes and market concerns regarding its research and development prospects [1] Group 1: Executive Changes - On February 12, the company announced that CEO Paul Hudson would step down, with Merck executive Belén Garijo set to take over in April. This unexpected change was interpreted by the market as a sign of the board's impatience due to the lack of expected results from R&D investments. The stock closed down 4.51% at $47.03, with an intraday low of $46.71 [2] Group 2: Company Fundamentals - Despite a 7% year-over-year revenue growth in Q4 2025 (13.3% growth at constant exchange rates), investors are more concerned about the risks associated with a weak R&D pipeline. In the past 12 months, the experimental multiple sclerosis drug tolebrutinib failed in key trials, and the clinical trial data for the atopic dermatitis candidate amlitelimab has been mixed. Jefferies reported that the management change may indicate slow progress in R&D transformation [3][4] Group 3: Performance and Operations - Dupixent accounts for over 30% of the company's revenue, but its patent is set to expire in the early 2030s, and Sanofi has not clearly identified new drugs to replace its revenue scale. Analysts from AlphaValue noted that investors have lost patience with repeated R&D failures, and the leadership change has intensified short-term uncertainty [4] Group 4: Industry Policy and Environment - The vaccine business contributes nearly 20% to revenue, but sales in Q4 declined by 2.5% year-over-year. The company expects this business to continue declining in 2026, with negative impacts from the U.S. policy environment on vaccine promotion. Additionally, the broader market decline, with the Nasdaq index falling by 2.03%, exacerbated the stock's drop [5]

Core Viewpoint - Sanofi has announced the sudden departure of CEO Paul Hudson, with Merck executive Belen Garijo taking over, as the company struggles with disappointing R&D results and investor dissatisfaction [1][2]. Group 1: Leadership Change - Paul Hudson has been at the helm of Sanofi for over six years, attempting to find a successor for the key drug Dupixent, which is facing a patent cliff [1]. - Belen Garijo, who has extensive experience with Sanofi, is expected to implement stricter execution of the company's strategy and improve R&D output and governance [1][2]. Group 2: R&D Challenges - Sanofi's aggressive new drug acceleration plan introduced by Hudson in 2023 has yet to yield substantial results, with key trials failing and regulatory setbacks [2]. - The company has faced mixed results in clinical trials for drugs intended to succeed Dupixent, leading to increased investor frustration [2]. Group 3: Company Strategy and Performance - Sanofi's divestment of its consumer health business means it will rely entirely on innovative prescription drugs moving forward [2]. - Analysts have noted that while Hudson restructured the company and set a growth path through 2030, the inability to improve R&D efficiency and find a successor for Dupixent has led to underperformance in valuation multiples compared to peers [2].

Core Insights - ImageneBio, Inc. has appointed Dr. Ben Porter-Brown as Chief Medical Officer to lead the clinical organization and the Phase 2b ADAPTIVE trial in atopic dermatitis [1][2][3] Company Overview - ImageneBio is a clinical-stage biotechnology company focused on developing therapeutics for immunological, autoimmune, and inflammatory diseases, with a specific emphasis on the anti-OX40 monoclonal antibody, IMG-007 [5] Leadership Appointment - Dr. Porter-Brown brings over 20 years of experience in autoimmune and inflammatory diseases, particularly in the OX40-OX40L inhibition field, and has previously held significant roles at MoonLake Immunotherapeutics and Kymab [3][4] - His expertise is expected to enhance the execution of the Phase 2b ADAPTIVE trial and the overall clinical strategy of Imagene [2][4] Clinical Development Plans - The Phase 2b ADAPTIVE trial will expand its footprint with planned international sites in the UK and Europe, aiming to address the treatment gap for patients with moderate-to-severe atopic dermatitis [1][4] - IMG-007 is positioned as a novel treatment option that may offer disease-modifying potential, differing from currently approved therapies [4] Financial Incentives - As part of his appointment, Dr. Porter-Brown will receive an inducement award of 137,000 shares of common stock, contingent upon his employment with a subsidiary in the UK [4]

Group 1 - Sanofi SA is considered one of the best cheap stocks to buy for 2026 according to Citi Research, which initiated coverage of six large European pharmaceutical stocks including Sanofi [1] - Citi assigned Sanofi a Neutral rating with a price target of €85, indicating concerns about the company's drug development progress and a weakened long-term growth outlook due to pipeline setbacks [2][3] - The current valuation of Sanofi is approximately 10 times expected 2026 earnings, reflecting the setbacks in its pipeline, and the market is unlikely to reward the stock with a higher multiple without tangible evidence of improvement [3] Group 2 - Sanofi reported positive results for its experimental medicine amlitelimab in Phase 3 clinical studies for moderate-to-severe atopic dermatitis, with data coming from two major global trials, SHORE and COAST 2 [4] - The results from the studies indicate that amlitelimab was generally well tolerated, with side effects consistent with previous findings [4] - Sanofi operates in various segments including specialty care, vaccines, and general medicines, focusing on the research, development, manufacturing, and marketing of pharmaceutical products [5]

Market Overview - The S&P 500 index briefly crossed 7000 points for the first time on January 28, 2026, rebounding nearly 40% since April 2025 lows, with five record closes noted by January 27, 2026 [1] - The Nasdaq Composite has seen modest gains in 2026, while the Russell 2000 has surged nearly 7% year-to-date as of January 29, 2026, outperforming large-cap peers for 14 consecutive trading sessions, the longest streak since 1996 [2] Valuation Concerns - The Shiller S&P 500 price-to-earnings ratio is currently at 41, the highest since the dot-com bubble, while the trailing P/E ratio is at 31.52, significantly above the historical average of 16.2 [3] - Bank of America's head of US equity strategy, Savita Subramanian, indicates that the S&P 500 is expensive, predicting it will reach 7,100 by year-end 2026, which is among the lowest forecasts on Wall Street [3] Investment Strategy - Goldman Sachs analysts predict that value stocks will remain favored if US economic momentum strengthens, noting that these stocks, with forward P/E ratios below 15, have outperformed higher-valuation stocks at the start of the year, achieving a 15% return in the last six months of 2025 [4] Stock Selection Methodology - The list of best cheap stocks for 2026 was created using screeners like TradingView and Finviz, focusing on US-listed stocks with forward P/E ratios between 3 and 15 and a positive upside potential of at least 20%, ranked by hedge fund holdings as of Q3 2025 [7][8] HNI Corporation - HNI Corporation (NYSE:HNI) is highlighted as a top cheap stock for 2026, with a forward P/E of 11.92 and an upside potential of 58.46% [9] - Benchmark Co. raised its price target for HNI to $75 per share from $60, citing a planned acquisition of Steelcase Inc. valued at approximately $2.2 billion, expected to yield annual cost synergies of about $120 million [10] - HNI's shares are priced below historical values, with a P/E ratio of 13.35, and the company has a history of consistent dividend payments over 55 years [11] Sanofi SA - Sanofi SA (NASDAQ:SNY) is also listed as a cheap stock for 2026, with a forward P/E of 9.02 and an upside potential of 25.11% [15] - Citi Research initiated coverage on Sanofi with a Neutral rating and an €85 price target, expressing concerns over pipeline setbacks affecting long-term growth [16] - Sanofi's current valuation reflects these setbacks, with analysts noting that the market is unlikely to reward the stock with a higher multiple without evidence of pipeline improvement [17] - Positive results were reported for Sanofi's experimental medicine amlitelimab in Phase 3 clinical studies for atopic dermatitis, indicating potential for future growth [18]

Business Finance Pipeline Appendices Business Finance Pipeline Appendices Results Q4/FY 2025 January 29, 2026 Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to fu ...

Core Viewpoint - Sanofi's strong sales performance of Dupixent has driven better-than-expected earnings for Q4 2025, with continued revenue and profit growth anticipated in 2026 [1] Financial Performance - Q4 2025 net sales reached €11.303 billion, a year-on-year increase of 7.0% (13.3% at constant exchange rates) [2] - Business operating income for Q4 was €2.341 billion, up 12.7% year-on-year [2] - Business net income for Q4 was €1.856 billion, reflecting a 13.0% increase year-on-year [2] - Business earnings per share (EPS) for Q4 was €1.53, a 16.8% increase compared to the previous year [2] - Free cash flow for Q4 was €2.637 billion, up 12.7% year-on-year [2] Product Performance - Dupixent sales grew by 32.2% year-on-year to a record €4.246 billion in Q4, solidifying its position as a key growth driver for Sanofi [2] - The pharmaceutical segment's sales increased by 49.4% to €1.121 billion, primarily driven by Ayvakit and ALTUVIIIO [2] Future Outlook - Sanofi expects sales growth in 2026 to be in the high single-digit percentage range (at constant exchange rates), with business EPS growth slightly exceeding sales growth [3] - The company plans to execute a €1 billion share buyback program in 2026 [3] Challenges and Strategic Focus - Sanofi's vaccine business faced a 2.5% decline in Q4 sales to €2.039 billion, with expectations of a slight decrease in vaccine sales for 2026 [3] - CEO Paul Hudson expressed optimism about sustained profit growth for at least five years, but emphasized the need for a robust pipeline to reduce reliance on Dupixent [4] - Recent disappointing trial results for new drugs have raised concerns about Sanofi's ability to generate sufficient revenue from upcoming products [4] - The company has written down €2.24 billion, primarily related to the failed multiple sclerosis drug tolebrutinib [4] Strategic Initiatives - Following the divestiture of its consumer health business, Sanofi is focused on demonstrating the success of its "pure innovation" strategy [5] - The company has engaged in significant partnerships, including a $1.04 billion collaboration with ADEL for an early-stage Alzheimer's antibody and a potential $1.7 billion deal with Dren Bio to enhance its autoimmune platform [5]